Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of ONL1204 in patients with macula-off rhegmatogenous retinal detachment has completed and posted results (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macula-off Retinal Detachment
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• ONL1204

Snippet

Sponsor: ONL Therapeutics | Conditions: Rhegmatogenous Retinal Detachment - Macula Off | Phase 1 | Status: COMPLETED | Results posted: 2024-09-24